A multicentre, uncontrolled trial on the contraceptive efficacy, safety, tolerability and pharmacokinetics of LPRI-424 (dienogest 2 mg / ethinyl estradiol 0.02 mg) during 13 cycles
Latest Information Update: 25 Sep 2023
At a glance
- Drugs Ethinylestradiol/dienogest (Primary)
- Indications Pregnancy
- Focus Registrational; Therapeutic Use
- Sponsors Chemo Research, S.L.
Most Recent Events
- 24 Sep 2023 This trial has been completed in Spain (Global end date: 26 May 2022).
- 21 Jul 2022 This trial has been completed in Bulgaria (end date 2022-05-26), according to European Clinical Trials Database record.
- 16 Jun 2022 This trial has been completed in Germany according to European Clinical Trials Database record.